S-托品酸 | 16202-15-6

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羟基酸及其衍生物
• 中文名称: S-托品酸
• 英文名称: (S)-tropic acid
• 英文别名: (S)-3-hydroxy-2-phenylpropanoic acid；L-tropic acid；(-)-tropic acid；(2S)-3-hydroxy-2-phenylpropanoic acid
• CAS: 16202-15-6
• 化学式: C₉H₁₀O₃
• 分子量: 166.177
• InChiKey: JACRWUWPXAESPB-MRVPVSSYSA-N

物化性质

• 熔点：
  126-127 °C
• 沸点：
  322.5±30.0 °C(Predicted)
• 密度：
  1.262±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2918199090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  | 室温 |

上下游信息

• 上游原料

  中文名称	英文名称	CAS号	化学式	分子量
  DL-托品酸	Tropic acid	552-63-6	C9H10O3	166.177
  Alpha-羟甲基苯乙酸甲酯	methyl tropate	3967-53-1	C10H12O3	180.203
  ——	α-phenyl-β-propiolactone	27150-91-0	C9H8O2	148.161
  ——	(S)-tropic acid lactone	135859-72-2	C9H8O2	148.161
  ——	3-chloro-2-phenyl-propionic acid	51545-26-7	C9H9ClO2	184.622
  ——	(+)-3-acetoxy-2-phenylpropionic acid	131682-38-7	C11H12O4	208.214
  2-苯基-1,3-丙二醇	2-phenylpropane-1, 3-diol	1570-95-2	C9H12O2	152.193
  ——	tropic acid butyl ester	——	C13H18O3	222.284

• 下游产品

  中文名称	英文名称	CAS号	化学式	分子量
  ——	(S)-methyl 3-hydroxy-2-phenylpropanoate	37778-97-5	C10H12O3	180.203

反应信息

• 作为反应物：
  描述：

  S-托品酸 在 盐酸 、 氯化亚砜 作用下， 反应 30.5h， 生成 hyoscyamine
  参考文献：
  名称：

  Differential analgesic activity of the enantiomers of atropine derivatives does not correlate with their muscarinic subtype selectivity

  摘要：

  The enantiomers of several tropic and p-substituted tropic acid esters related to atropine obtained by esterification under non-racemizing conditions after resolution of the corresponding racemic acids [(+)- and (-)-18, (+)- and (-)-19] are reported. They were tested in vitro on muscarinic subtype receptors and in vivo for their analgesic activity on mice. As in the case of the lead compound, R-(+)-hyoscyamine, these substances show enantioselectivity in analgesic tests, the eutomers being the R-(+) or R-(+)-p-substituted tropic acid derivatives. However, this property, which is a consequence of increased central release of ACh, seems unrelated to muscarinic subtype selectivity insofar as the compounds are unable to discriminate muscarinic subtype receptors. A possible explanation of these results which does not involve subtype selectivity is proposed, based on the recently developed concept of inverse agonism.

  DOI：

  10.1016/s0223-5234(97)83285-0
• 作为产物：
  描述：

  [(2R)-2-(2,4-dichlorophenyl)-3-hydroxypropyl] acetate 在 palladium on activated charcoal chromium(III) oxide 、 氢氧化钾 、 氢气 作用下， 以 甲醇 为溶剂， 生成 S-托品酸
  参考文献：
  名称：

  Bianchi, Daniele; Cesti, Pietro; Golini, Paolo, Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1993, vol. 32, # 1, p. 176 - 180

  摘要：

  DOI：

文献信息

• [EN] MUSCARINIC RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DE RECEPTEURS MUSCARINIQUES
  申请人：RANBAXY LAB LTD

  公开号：WO2006035303A1

  公开（公告）日：2006-04-06

  This present invention generally relates to muscarinic receptor antagonists of Formula (I), which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to the process for the prepration of disclosed compounds, pharmaceutical compositions containing the disclosed compounds, and the methods for treating diseases mediated through muscarinic receptors.

  本发明通常涉及公式（I）的肌氨酸受体拮抗剂，该类拮抗剂可用于治疗通过肌氨酸受体介导的呼吸系统、泌尿系统和消化系统的各种疾病，此外，该发明还涉及所述化合物的制备过程、含有所述化合物的药物组合物，以及治疗通过肌氨酸受体介导的疾病的方法。
• 7β-Hydroxyhyoscyamine from Duboisia myoporoides-D. leichhardtii hybrid and Hyoscyamus albus
  作者：Kanji Ishimaru、Koichiro Shimomura

  DOI：10.1016/0031-9422(89)80374-7

  日期：1989.1

  Abstract A new tropane alkaloid, 7β-hydroxyhyoscyamine was isolated, together with 6β-hydroxyhyoscyamine, hyoscyamine, norhyoscyamine, scopolamine and tropine, from the leaves of Duboisia hybrid M-II-8-6 (crossbred between D. myoporoides and D. leichhardtii ) and the hairy roots of Hyoscyamus albus .

  摘要 从D. myoporoides 和D. leichhardtii 杂交的Duboisia 杂种M-II-8-6 的叶子中分离到了一种新的莨菪烷生物碱7β-羟基莨菪碱，以及6β-羟基莨菪碱、莨菪碱、正莨菪碱、东莨菪碱和托品。和Hyoscyamus albus的毛根。
• AMINO ACID COMPOUNDS AND METHODS OF USE
  申请人：Pliant Therapeutics, Inc.

  公开号：US20200109141A1

  公开（公告）日：2020-04-09

  The invention relates to compounds of formula (I): or a salt thereof, wherein R 1 , G, L 1 , L 2 , L 3 , and Y are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are inhibitors of one, or both of, αvβ 1 integrin and αvβ 6 integrin that are useful for treating fibrosis such as in nonalcoholic steatohepatitis (NASH), idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).

  本发明涉及如下公式(I)的化合物： 或其盐，其中R1、G、L1、L2、L3和Y如本文所述。公式(I)的化合物及其药物组合物是αvβ1整合素和/或αvβ6整合素的一种或两种的抑制剂，用于治疗纤维化，如非酒精性脂肪肝炎（NASH）、特发性肺纤维化（IPF）和非特异性间质性肺炎（NSIP）。
• Molecular modification of anticholinergics as probes for muscarinic receptors. 1. Amino esters of .alpha.-substituted phenylacetic acid and related analogs
  作者：Matthias C. Lu、Walley E. Wung、Lisa B. Shih、Soledad Callejas、James E. Gearien、Emmanuel B. Thompson

  DOI：10.1021/jm00385a008

  日期：1987.2

  Two series of compounds having the general structure of C6H5CRR'COOCH2CH2NEt2 were synthesized and examined for their antispasmodic activities. These compounds were selected as structural probes for exploring the nature of muscarinic cholinergic receptor binding sites that interact with atropine-like anticholinergics. These studies indicate a rather strict size limitation for the hydrophobic region

  合成了具有C6H5CRR'COOCH2CH2NEt2的一般结构的两个系列的化合物，并研究了它们的解痉活性。选择这些化合物作为结构探针，以探索与阿托品样抗胆碱能药物相互作用的毒蕈碱胆碱能受体结合位点的性质。这些研究表明，对于受体的疏水区域存在相当严格的尺寸限制，并建议分子内氢键作为解释观察到的立体选择性的可能手段。
• [EN] PYRROLIDINE-PYRAZOLES AS PYRUVATE KINASE ACTIVATORS<br/>[FR] PYRROLIDINE-PYRAZOLES EN TANT QU'ACTIVATEURS DE LA PYRUVATE KINASE
  申请人：GLOBAL BLOOD THERAPEUTICS INC

  公开号：WO2021202796A1

  公开（公告）日：2021-10-07

  The subject matter described herein is directed to pyruvate kinase activating compounds of Formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds and methods of administering the compounds for the treatment of diseases associated with PKR and/or PKM2, such as pyruvate kinase deficiency, sickle cell disease, and beta-thalassemia.

  本文描述的主题是针对式I的丙酮酸激酶激活化合物及其药用盐，制备这些化合物的方法，包含这些化合物的药物组合物以及用于治疗与PKR和/或PKM2相关疾病的化合物的给药方法，例如丙酮酸激酶缺乏症、镰状细胞病和β地中海贫血。